Cefiderocol Shows Promise in Phase 3 Studies, But Questions Remain
October 19, 2020
Cefiderocol was noninferior to high-dose, extended-infusion meropenem in terms of all-case mortality in patients with gram-negative nosocomial pneumonia and showed similar clinical and microbiological efficacy to best available therapies in carbapenem-resistant, gram-negative bacterial infections, according to 2 recently released studies.
